“Changing the Medicare prescription drug benefit based on inaccurate and misleading information will only hurt beneficiaries,” Ken Johnson, senior vice president of PhRMA writes in a Chicago Sun-Times letter to the editor. Johnson’s letter is in response to a Nov. [click link for full article]